E2F4 Predictive of Progression and Immunotherapy Efficacy in Bladder Cancer

Targeted Oncology - Quotes Chao Cheng, assistant professor of genetics and lead author of a recent study on the biomarker E2F4. The biomarker predicts survival in breast cancer, and Cheng's research suggests that E2F4 may also predict progression and immunotherapy efficacy in bladder cancer. "The E2F4 signature was identified from a computational analysis for identifying breast cancer-associated transcriptional regulatory programs," says Cheng. "Later, we found the signature is also effective in predicting the clinical outcomes of bladder cancer. Since the E2F4 signature reflects the proliferation of tumor cells, which is clinically related in diverse solid tumors, we anticipate that it might also be useful in other solid tumor types, such as prostate cancer."